N-myc augments death and attenuates protective effects of Bcl-2 in trophically stressed neuroblastoma cells

Oncogene

Volumn 27, Issue 24, 2008, Pages 3424-3434

  Ushmorov, A ^a,c   Hogarty, M D ^b   Liu, X ^b   Knauss H ^a   Debatin, K M ^a   Beltinger, C ^a  

^a UNIVERSITY HOSPITAL ULM   (Germany)

^b CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^c UNIVERSITY OF ULM   (Germany)

Author keywords

Bcl 2; FLIPL; N myc; Neuroblastoma; Survivin

Indexed keywords

4 HYDROXYTAMOXIFEN; FLICE INHIBITORY PROTEIN; PROTEIN BCL 2; SURVIVIN;

APOPTOSIS; ARTICLE; CONTROLLED STUDY; GENE EXPRESSION; HUMAN; HUMAN CELL; METABOLIC STRESS; NEUROBLASTOMA; NEUROBLASTOMA CELL; ONCOGENE C MYB; OXIDATIVE PHOSPHORYLATION; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

APOPTOSIS; BLOTTING, WESTERN; CASP8 AND FADD-LIKE APOPTOSIS REGULATING PROTEIN; CASPASES; CELL SURVIVAL; CULTURE MEDIA, SERUM-FREE; GENE EXPRESSION REGULATION, NEOPLASTIC; GLYCOLYSIS; HUMANS; MICROTUBULE-ASSOCIATED PROTEINS; NEOPLASM PROTEINS; NEUROBLASTOMA; OXIDATIVE STRESS; PHENOTYPE; PHOSPHORYLATION; PROTEIN TRANSPORT; PROTO-ONCOGENE PROTEINS C-BCL-2; PROTO-ONCOGENE PROTEINS C-MYC; RETROVIRIDAE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TAMOXIFEN; TUMOR CELLS, CULTURED;

EID: 44449160893     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/sj.onc.1211017     Document Type: Article

References (58)

1. Adida C, Berrebi D, Peuchmaur M, Reyes-Mugica M, Altieri DC. (1998). Anti-apoptosis gene, survivin, and prognosis of neuroblastoma. Lancet 351: 882-883.
2. Altieri DC. (2003). Survivin, versatile modulation of cell division and apoptosis in cancer. Oncogene 22: 8581-8589.
3. Ambrosini G, Adida C, Altieri DC. (1997). A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 3: 917-921.
4. Boatright KM, Deis C, Denault JB, Sutherlin DP, Salvesen GS. (2004). Activation of caspases-8 and -10 by FLIP(L). Biochem J 382: 651-657.
5. Boon K, Caron HN, van Asperen R, Valentijn L, Hermus MC, van Sluis P et al. (2001). N-myc enhances the expression of a large set of genes functioning in ribosome biogenesis and protein synthesis. EMBO J 20: 1383-1393.
6. Breit S, Schwab M. (1989). Suppression of MYC by high expression of NMYC in human neuroblastoma cells. J Neurosci Res 24: 21-28.
7. Brodeur GM, Seeger RC, Schwab M, Varmus HE, Bishop JM. (1984). Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. Science 224: 1121-1124.
8. Brummelkamp TR, Bernards R, Agami R. (2002). A system for stable expression of short interfering RNAs in mammalian cells. Science 296: 550-553.
9. Castle VP, Heidelberger KP, Bromberg J, Ou X, Dole M, Nunez G. (1993). Expression of the apoptosis-suppressing protein bcl-2, in neuroblastoma is associated with unfavorable histology and N-myc amplification. Am J Pathol 143: 1543-1550.
10. Chan HS, Gallie BL, DeBoer G, Haddad G, Ikegaki N, Dimitroulakos J et al. (1997). MYCN protein expression as a predictor of neuroblastoma prognosis. Clin Cancer Res 3: 1699-1706.
11. Chang DW, Xing Z, Pan Y, Algeciras-Schimnich A, Barnhart BC, Yaish-Ohad S et al. (2002). c-FLIP(L) is a dual function regulator for caspase-8 activation and CD95-mediated apoptosis. EMBO J 21: 3704-3714.
12. Cohn SL, London WB, Huang D, Katzenstein HM, Salwen HR, Reinhart T et al. (2000). MYCN expression is not prognostic of adverse outcome in advanced-stage neuroblastoma with nonamplified MYCN. J Clin Oncol 18: 3604-3613.
13. Dohi T, Beltrami E, Wall NR, Plescia J, Altieri DC. (2004). Mitochondrial survivin inhibits apoptosis and promotes tumorigenesis. J Clin Invest 114: 1117-1127.
14. Eggert A, Grotzer MA, Zuzak TJ, Wiewrodt BR, Ho R, Ikegaki N et al. (2001). Resistance to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in neuroblastoma cells correlates with a loss of caspase-8 expression. Cancer Res 61: 1314-1319.
15. Fantin VR, St-Pierre J, Leder P. (2006). Attenuation of LDH-A expression uncovers a link between glycolysis, mitochondrial physiology, and tumor maintenance. Cancer Cell 9: 425-434.
16. Fischer M, Skowron M, Berthold F. (2005). Reliable transcript quantification by real-time reverse transcriptase-polymerase chain reaction in primary neuroblastoma using normalization to averaged expression levels of the control genes HPRT1 and SDHA. J Mol Diagn 7: 89-96.
17. Fulda S, Lutz W, Schwab M, Debatin KM. (1999). MycN sensitizes neuroblastoma cells for drug-induced apoptosis. Oncogene 18: 1479-1486.
18. Fulda S, Poremba C, Berwanger B, Hacker S, Eilers M, Christiansen H et al. (2006). Loss of caspase-8 expression does not correlate with MYCN amplification, aggressive disease, or prognosis in neuroblastoma. Cancer Res 66: 10016-10023.
19. Ganten TM, Haas TL, Sykora J, Stahl H, Sprick MR, Fas SC et al. (2004). Enhanced caspase-8 recruitment to and activation at the DISC is critical for sensitisation of human hepatocellular carcinoma cells to TRAIL-induced apoptosis by chemotherapeutic drugs. Cell Death Differ 11(Suppl 1): S86-S96.
20. Goldsmith KC, Hogarty MD. (2005). Targeting programmed cell death pathways with experimental therapeutics: opportunities in high-risk neuroblastoma. Cancer Lett 228: 133-141.
21. Hogarty MD. (2003). The requirement for evasion of programmed cell death in neuroblastomas with MYCN amplification. Cancer Lett 197: 173-179.
22. Hopkins-Donaldson S, Bodmer JL, Bourloud KB, Brognara CB, Tschopp J, Gross N. (2000). Loss of caspase-8 expression in highly malignant human neuroblastoma cells correlates with resistance to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis. Cancer Res 60: 4315-4319.
23. Hueber AO, Zornig M, Lyon D, Suda T, Nagata S, Evan GI. (1997). Requirement for the CD95 receptor-ligand pathway in c-Myc-induced apoptosis. Science 278: 1305-1309.
24. Ichimiya S, Nimura Y, Kageyama H, Takada N, Sunahara M, Shishikura T et al. (1999). p73 at chromosome 1p36.3 is lost in advanced stage neuroblastoma but its mutation is infrequent. Oncogene 18: 1061-1066.
25. Islam A, Kageyama H, Takada N, Kawamoto T, Takayasu H, Isogai E et al. (2000). High expression of survivin, mapped to 17q25, is significantly associated with poor prognostic factors and promotes cell survival in human neuroblastoma. Oncogene 19: 617-623.
26. Jasty R, van Golen C, Lin HJ, Solomon G, Heidelberger K, Polverini P et al. (2001). Bcl-2 and n-myc coexpression increases igf-ir and features of malignant growth in neuroblastoma cell lines. Neoplasia 3: 304-313.
27. Juin P, Hueber AO, Littlewood T, Evan G. (1999). c-Myc-induced sensitization to apoptosis is mediated through cytochrome c release. Genes Dev 13: 1367-1381.
28. Kim YH, Kim SS. (2003). Bcl-2 inhibits tumor necrosis factor-alpha-mediated increase of glycolytic enzyme activities and enhances pyruvate carboxylase activity. Mol Cells 16: 67-73.
29. Krueger A, Baumann S, Krammer PH, Kirchhoff S. (2001). FLICE-inhibitory proteins: regulators of death receptor-mediated apoptosis. Mol Cell Biol 21: 8247-8254.
30. Lens SM, Wolthuis RM, Klompmaker R, Kauw J, Agami R, Brummelkamp T et al. (2003). Survivin is required for a sustained spindle checkpoint arrest in response to lack of tension. EMBO J 22: 2934-2947.
31. Liu X, Mazanek P, Dam V, Wang Q, Zhao H, Guo R et al. (2007). Deregulated Wnt/beta-catenin program in high-risk neuroblastomas without MYCN amplification. Oncogene 27 (e-pub ahead of print).
32. Look AT, Hayes FA, Shuster JJ, Douglass EC, Castleberry RP, Bowman LC et al. (1991). Clinical relevance of tumor cell ploidy and N-myc gene amplification in childhood neuroblastoma: a Pediatric Oncology Group Study. J Clin Oncol 9: 581-591.
33. Matthay KK. (2000). MYCN expression in neuroblastoma: a mixed message? J Clin Oncol 18: 3591-3594.
34. Micheau O, Thome M, Schneider P, Holler N, Tschopp J, Nicholson DW et al. (2002). The long form of FLIP is an activator of caspase-8 at the Fas death-inducing signaling complex. J Biol Chem 277: 45162-45171.
35. Miller MA, Ohashi K, Zhu X, McGrady P, London WB, Hogarty M et al. (2006). Survivin mRNA levels are associated with biology of disease and patient survival in neuroblastoma: a report from the Children's Oncology Group. J Pediatr Hematol Oncol 28: 412-417.
36. Nakagawara A, Kadomatsu K, Sato S, Kohno K, Takano H, Akazawa K et al. (1990). Inverse correlation between expression of multidrug resistance gene and N-myc oncogene in human neuroblastomas. Cancer Res 50: 3043-3047.
37. Nicoletti I, Migliorati G, Pagliacci MC, Grignani F, Riccardi C. (1991). A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J Immunol Methods 139: 271-279.
38. Nilsson JA, Cleveland JL. (2003). Myc pathways provoking cell suicide and cancer. Oncogene 22: 9007-9021.
39. Nisen PD, Waber PG, Rich MA, Pierce S, Garvin Jr JR, Gilbert F et al. (1988). N-myc oncogene RNA expression in neuroblastoma. J Natl Cancer Inst 80: 1633-1637.
40. Papas KK, Sun L, Roos ES, Gounarides JS, Shapiro M, Nalin CM. (1999). Change in lactate production in Myc-transformed cells precedes apoptosis and can be inhibited by Bcl-2 overexpression. FEBS Lett 446: 338-342.
41. Poulaki V, Mitsiades N, Romero ME, Tsokos M. (2001). Fas-mediated apoptosis in neuroblastoma requires mitochondrial activation and is inhibited by FLICE inhibitor protein and Bcl-2. Cancer Res 61: 4864-4872.
42. Ricci-Vitiani L, Pedini F, Mollinari C, Condorelli G, Bonci D, Bez A et al. (2004). Absence of caspase-8 and high expression of PED protect primitive neural cells from cell death. J Exp Med 200: 1257-1266.
43. Ross RA, Spengler BA, Biedler JL. (1983). Coordinate morphological and biochemical interconversion of human neuroblastoma cells. J Natl Cancer Inst 71: 741-747.
44. Roth W, Reed JC. (2004). FLIP protein and TRAIL-induced apoptosis. Vitam Horm 67: 189-206.
45. Schweigerer L, Breit S, Wenzel A, Tsunamoto K, Ludwig R, Schwab M. (1990). Augmented MYCN expression advances the malignant phenotype of human neuroblastoma cells: evidence for induction of autocrine growth factor activity. Cancer Res 50: 4411-4416.
46. Seeger RC, Brodeur GM, Sather H, Dalton A, Siegel SE, Wong KY et al. (1985). Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. N Engl J Med 313: 1111-1116.
47. Sharp DA, Lawrence DA, Ashkenazi A. (2005). Selective knockdown of the long variant of cellular FLICE inhibitory protein augments death receptor-mediated caspase-8 activation and apoptosis. J Biol Chem 280: 19401-19409.
48. Shim H, Chun YS, Lewis BC, Dang CV. (1998). A unique glucose-dependent apoptotic pathway induced by c-Myc. Proc Natl Acad Sci USA 95: 1511-1516.
49. Shim H, Dolde C, Lewis BC, Wu CS, Dang G, Jungmann RA et al. (1997). c-Myc transactivation of LDH-A: implications for tumor metabolism and growth. Proc Natl Acad Sci USA 94: 6658-6663.
50. Slavc I, Ellenbogen R, Jung WH, Vawter GF, Kretschmar C, Grier H et al. (1990). Myc gene amplification and expression in primary human neuroblastoma. Cancer Res 50: 1459-1463.
51. Song J, So T, Cheng M, Tang X, Croft M. (2005). Sustained survivin expression from OX40 costimulatory signals drives T cell clonal expansion. Immunity 22: 621-631.
52. Stupack DG, Teitz T, Potter MD, Mikolon D, Houghton PJ, Kidd VJ et al. (2006). Potentiation of neuroblastoma metastasis by loss of caspase-8. Nature 439: 95-99.
53. Tang XX, Zhao H, Kung B, Kim DY, Hicks SL, Cohn SL et al. (2006). The MYCN enigma: significance of MYCN expression in neuroblastoma. Cancer Res 66: 2826-2833.
54. Teitz T, Wei T, Valentine MB, Vanin EF, Grenet J, Valentine VA et al. (2000). Caspase 8 is deleted or silenced preferentially in childhood neuroblastomas with amplification of MYCN [see comments]. Nat Med 6: 529-535.
55. Ueda K, Ganem D. (1996). Apoptosis is induced by N-myc expression in hepatocytes, a frequent event in hepadnavirus oncogenesis, and is blocked by insulin-like growth factor II. J Virol 70: 1375-1383.
56. van de Wetering M, Sancho E, Verweij C, de Lau W, Oving I, Hurlstone A et al. (2002). The beta-catenin/TCF-4 complex imposes a crypt progenitor phenotype on colorectal cancer cells. Cell 111: 241-250.
57. Vaupel P. (2004). Tumor microenvironmental physiology and its implications for radiation oncology. Semin Radiat Oncol 14: 198-206.
58. Wada RK, Seeger RC, Brodeur GM, Einhorn PA, Rayner SA, Tomayko MM et al. (1993). Human neuroblastoma cell lines that express N-myc without gene amplification. Cancer 72: 3346-3354.